Latest Direct thrombin inhibitor Stories
-Direct Oral Anticoagulant Measurement, Automated on ACL TOP® Family of Hemostasis Testing Systems- BEDFORD, Mass., Sept.
Clinicians from the University of Utah report the death of a patient who received a mild brain injury from a ground-level fall while taking the new anticoagulant dabigatran etexilate for non–valve related atrial fibrillation.
Researchers at the University of Cincinnati and Massachusetts General Hospital have found that warfarin, a known anticoagulation (blood-thinning) drug, may not be as beneficial to some patients with atrial fibrillation as previously thought.
RIDGEFIELD, Conn., Sept. 20 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee today voted 9 to 0 in favor of approving dabigatran etexilate for stroke prevention in patients with atrial fibrillation (AFib).
RIDGEFIELD, Conn., Aug. 29 /PRNewswire/ -- Boehringer Ingelheim today announced results from a pre-specified, retrospective, un-blinded sub-analysis of the RE-LYÂ® trial - the largest atrial fibrillation outcomes trial ever conducted(2) - were published in The Lancet.
Study highlights: - A new anti-clotting drug proved as effective as the blood thinner currently used to prevent stroke in atrial fibrillation patients with prior stroke or transient ischemic attacks - The lower dose of the drug dabigatran produced less risk of bleeding in the brain than warfarin did - Dabigatran is not approved in the United States but is available in other countries to prevent blood clots after elective hip and knee replacement surgery SAN ANTONIO, Feb.
In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as warfarin, but with fewer side effects.
RIDGEFIELD, Conn., Aug.
- A trick or prank.